Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment

Sub-indication: Miscellaneous Malignancies

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Seattle Genetics, Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.